

## Special Issue

# Selected Papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023)

### Message from the Guest Editors

This Special Issue comprises selected papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023), hosted online from 1 to 15 December 2023, an online platform for hosting scholarly e-conferences and discussion groups (<https://iecv2023.sciforum.net/>).

- Vaccines to counter anti-microbial resistance;
- Vaccines to eradicate endemic disease—opportunities and challenges;
- Vaccines to prevent zoonotic transmission—targeting the animal reservoir;
- Vaccine platforms—advantages and disadvantages;
- Clinical trial design for reactive and preventive vaccination;
- Vaccine deployment in outbreak settings—lessons learned;
- Advances in vaccine formulation and adjuvantisation;
- Clinical view on routinisation of RNA vaccines;
- Immune response after vaccination against SARS-CoV-2 in patients with chronic diseases;
- T-cell responses in SARS-CoV-2;
- Novel technology and vaccines development for COVID-19;
- T-cell immunity and HIV-1 pathogenicity;
- Vaccine hesitancy;

---

### Guest Editors

Dr. François Meurens

Swine and Poultry Infectious Diseases Research Center (CRIPA),  
Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe,  
QC J2S 2M2, Canada

Dr. Fanny Renois

BIOEPAR, INRAE, Oniris, 44307 Nantes, France

---

**Deadline for manuscript submissions**



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/178441](https://mdpi.com/si/178441)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).